Compare BTU & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | ICUI |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.6B |
| IPO Year | N/A | 1992 |
| Metric | BTU | ICUI |
|---|---|---|
| Price | $30.61 | $139.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $26.83 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 2.5M | 213.3K |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,962,300,000.00 | $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.61 | $107.00 |
| 52 Week High | $35.99 | $175.51 |
| Indicator | BTU | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 40.50 |
| Support Level | $29.50 | $146.11 |
| Resistance Level | $31.08 | $149.00 |
| Average True Range (ATR) | 1.26 | 3.50 |
| MACD | 0.03 | -1.27 |
| Stochastic Oscillator | 65.89 | 8.25 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan and other regions.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.